Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to unlock XLH mysteries in adults

NCT ID NCT07607600

Not yet recruiting Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 100 adults with X-linked hypophosphatemia (XLH) who are already taking burosumab. Researchers want to see how phosphate levels change over time and how they relate to bone health and overall disease burden. The goal is to better understand the condition and improve future management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could provide clearer guidance on managing XLH with burosumab, potentially improving bone health and quality of life for patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for X-LINKED HYPOPHOSPHATEMIA (XLH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

X-linked dominant hypophosphatemic rickets X-linked hypophosphatemic rickets

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

X-LINKED HYPOPHOSPHATEMIA (XLH)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Azienda Ospedaliera di Padova - U.O.C. di Gastroenterologia

    Padova, 35128, Italy

  • Bone Research and Education Centre

    Oakville, Ontario, L6M 1M1, Canada

  • CHU de Bicetre

    Le Kremlin, 94275, France

  • Charite Campus Virchow

    Berlin, 13353, Germany

  • Endokrinologikum Goettingen

    Göttingen, 37075, Germany

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, 00128, Italy

  • Fukuoka University - Fukuoka University Hospital

    Fukuoka, Fukuoka, 814-0180, Japan

  • Hopital Cochin - APHP

    Paris, 75014, France

  • Indiana University Hospital

    Indianapolis, Indiana, 46202-5271, United States

  • Iseikai International General Hospital

    Osaka, 530-0052, Japan

  • Istituto Auxologico Italiano

    Milan, 20145, Italy

  • Japan Community Healthcare Organization Osaka Hospital

    Osaka, 553-0003, Japan

  • Leiden University Medical Center (Leids Universitair Medisch Centrum (LUMC))

    Leiden, 2333 ZA, Netherlands

  • Monash University - Monash Medical Centre (MMC)

    Clayton, Victoria, 3168, Australia

  • Northern Sydney Cancer Centre-Royal North Shore Hospital (RNSH)

    St Leonards, New South Wales, 2065, Australia

  • Office of Francesco Di Costanzo, MD

    Sesto Fiorentino, Florence, 50019, Italy

  • Okayama Saiseikai Outpatient Center Hospital

    Okayama, Okayama-ken, 700-0013, Japan

  • The Ohio State University Wexner Medical Center (OSUWMC) - CarePoint East

    Columbus, Ohio, 43203, United States

  • The University of Tokyo Hospital

    Bunkyo-ku, Tokyo, 113-8655, Japan

  • Universitat Wurzburg Koenig-Ludwig-Haus

    Wuezburg, 97074, Germany

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232-8148, United States

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

  • Yale University School of Medicine

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.